Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2BTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3MPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PPARGSLC6A2SLC6A3SLC6A4SMOTYK2pol
The experimentally established mechanism targets of Perazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A known ✓ | P08908 | 5/20 | 0.64 |
| ▸ | ADRA2A known ✓ | P08913 | 5/20 | 0.64 |
| ▸ | DRD2 known ✓ | P14416 | 5/20 | 0.64 |
| ▸ | ADRA2C known ✓ | P18825 | 5/20 | 0.64 |
| ▸ | DRD1 known ✓ | P21728 | 5/20 | 0.64 |
| ▸ | SLC6A2 known ✓ | P23975 | 5/20 | 0.64 |
| ▸ | HTR2A known ✓ | P28223 | 5/20 | 0.64 |
| ▸ | SLC6A4 known ✓ | P31645 | 5/20 | 0.64 |
| ▸ | ADRA1A known ✓ | P35348 | 5/20 | 0.64 |
| ▸ | HRH1 known ✓ | P35367 | 5/20 | 0.64 |
| ▸ | SLC6A3 known ✓ | Q01959 | 5/20 | 0.64 |
| ▸ | ADRA2B known ✓ | P18089 | 4/20 | 0.64 |
| ▸ | HTR2C known ✓ | P28335 | 3/20 | 0.64 |
| ▸ | HTR2B known ✓ | P41595 | 3/20 | 0.64 |
| ▸ | MTOR known ✓ | P42345 | 2/20 | 0.64 |
| ▸ | ADRB1 known ✓ | P08588 | 1/20 | 0.64 |
| ▸ | ADRA1D known ✓ | P25100 | 1/20 | 0.64 |
| ▸ | HRH3 known ✓ | Q9Y5N1 | 4/20 | 0.60 |
| ▸ | MAPT | P10636 | 5/20 | 0.82 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Perazine SCHEMBL220704 | 1.00 | MAPT (0.82) | MAPTMAPK1LMNASMN1; SMN2NPSR1 | |
| Perazine SCHEMBL10531680 | 0.91 | KDM1A (0.84) | MAPTMAPK1LMNASMN1; SMN2NPSR1 | |
| Prochlorperazine SCHEMBL40756 | 0.91 | LMNA (1.00) | MAPTMAPK1LMNASMN1; SMN2NPSR1 | |
| Prochlorperazine SCHEMBL8911628 | 0.91 | LMNA (1.00) | MAPTMAPK1LMNASMN1; SMN2NPSR1 | |
| Prochlorperazine SCHEMBL29634451 | 0.91 | LMNA (1.00) | MAPTMAPK1LMNASMN1; SMN2NPSR1 | |
| Prochlorperazine SCHEMBL1806022 | 0.91 | LMNA (1.00) | MAPTMAPK1LMNASMN1; SMN2NPSR1 | |
| Prochlorperazine SCHEMBL718254 | 0.91 | LMNA (1.00) | MAPTMAPK1LMNASMN1; SMN2NPSR1 | |
| Prochlorperazine SCHEMBL40755 | 0.91 | LMNA (1.00) | MAPTMAPK1LMNASMN1; SMN2NPSR1 | |
| Prochlorperazine SCHEMBL5494383 | 0.91 | LMNA (1.00) | MAPTMAPK1LMNASMN1; SMN2NPSR1 | |
| Prochlorperazine SCHEMBL29686418 | 0.91 | LMNA (1.00) | MAPTMAPK1LMNASMN1; SMN2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11246873-B2 | Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate | THE SCRIPPS RESEARCH INSTITUTE (US) | 2022-02-15 | — | — | US | disclosed |
| EP-3181616-B1 | CELLULOSE MICROPOWDER | ASAHI CHEMICAL IND (JP) | 2021-09-15 | — | — | EP | disclosed |
| US-10940150-B2 | Thymine derivatives and quinazoline-dione derivatives for the inhibition of HSP27 | TECHNISCHE UNIVERSITAET DRESDEN (DE) | 2021-03-09 | — | — | US | disclosed |
| US-20200390780-A1 | DIRECTED DIFFERENTIATION OF OLIGODENDROCYTE PRECURSOR CELLS TO A MYELINATING CELL FATE | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2020-12-17 | — | — | US | disclosed |
| EP-2486917-B1 | COATING FILM, AND GRANULES AND TABLETS EACH UTILIZING SAME | ASAHI CHEMICAL IND (JP) | 2020-11-25 | — | — | EP | disclosed |
| US-10660899-B2 | Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate | THE SCRIPPS RESEARCH INSTITUTE (US) | 2020-05-26 | — | — | US | disclosed |
| EP-2184056-B1 | PROCESS FOR PRODUCTION OF TABLETS CONTAINING BOTH CRYSTALLINE CELLULOSE AND GRANULES | ASAHI CHEMICAL IND (JP) | 2019-04-24 | — | — | EP | disclosed |
| US-20180207160-A1 | THYMINE DERIVATIVES AND QUINAZOLINE-DIONE DERIVATIVES FOR THE INHIBITION OF HSP27 | TECHNISCHE UNIVERSITAET DRESDEN (DE) | 2018-07-26 | — | — | US | disclosed |
| US-10016367-B2 | Cellulose micropowder | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2018-07-10 | — | — | US | disclosed |
| US-20170258728-A1 | CELLULOSE MICROPOWDER | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2017-09-14 | — | — | US | disclosed |
| CN-1473054-A | Cellulose particles for pharmaceutical preparations | ������������ʽ���� | 2004-02-04 | — | — | CN | disclosed |
| US-20030203016-A1 | Freeze-dried agent containing paramylon, its production and use | SUWELACK WOLFGANG (DE) | 2003-10-30 | — | — | US | disclosed |
| EP-1341527-A1 | PHARMACEUTICAL PREPARATION COMPRISING AN ACTIVE DISPERSED ON A MATRIX | ALTANA Pharma AG (DE) | 2003-09-10 | — | — | EP | disclosed |
| EP-1338288-A1 | CELLULOSIC PARTICLE FOR PHARMACEUTICAL PREPARATION | Asahi Kasei Kabushiki Kaisha (JP) | 2003-08-27 | — | — | EP | disclosed |
| US-20030049325-A1 | Agent for oral intake, its production and use | SUWELACK WOLFGANG (DE) | 2003-03-13 | — | — | US | disclosed |
| WO-2002045693-A1 | PHARMACEUTICAL PREPARATION COMPRISING AN ACTIVE DISPERSED ON A MATRIX | ALTANA PHARMA AG (DE) | 2002-06-13 | — | — | WO | disclosed |
| US-5830497-A | Medicated plaster containing basic physiologically active agents and/or salts thereof | NITTO DENKO CORPORATION (JP) | 1998-11-03 | — | — | US | disclosed |
| EP-0387751-B1 | Medicated plasters | NITTO DENKO CORP (JP) | 1994-06-08 | — | — | EP | disclosed |
| EP-0387751-A2 | Medicated plasters | NITTO DENKO CORPORATION (JP) | 1990-09-19 | — | — | EP | disclosed |
| EP-0233009-A2 | System for delivering drug with enhanced bioacceptability | ALZA CORPORATION (US) | 1987-08-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180207160-A1 | THYMINE DERIVATIVES AND QUINAZOLINE-DIONE DERIVATIVES FOR THE INHIBITION OF HSP27 | HSPB1, HSP90B1, HSP90AB1 | HTR1A 2936/4885ADRA2A 1614/4885DRD2 3742/4885 |
| US-10940150-B2 | Thymine derivatives and quinazoline-dione derivatives for the inhibition of HSP27 | HSPB1, HSP90B1, HSP90AB1 | HTR1A 2936/4885ADRA2A 1614/4885DRD2 3742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.